Epigenetics of autoimmune diabetes

Epigenomics

Volumn 3, Issue 5, 2011, Pages 639-648

  Jayaraman, Sundararajan ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

diabetes; epigenetics; histone deacetylase inhibitors; miRNAs

Indexed keywords

BENZAMIDE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HISTONE METHYLTRANSFERASE; HYDROXAMIC ACID; MAJOR HISTOCOMPATIBILITY ANTIGEN; ROMIDEPSIN; SHORT CHAIN FATTY ACID; TETRAPEPTIDE; TRICHOSTATIN A; UNTRANSLATED RNA;

CHROMATIN ASSEMBLY AND DISASSEMBLY; DEACETYLATION; DIABETOGENESIS; DNA METHYLATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; ENVIRONMENTAL FACTOR; ENZYME INHIBITION; EPIGENETICS; GENE EXPRESSION REGULATION; GENOTYPE ENVIRONMENT INTERACTION; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATORY DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ACETYLATION; ANIMALS; CHROMATIN ASSEMBLY AND DISASSEMBLY; DIABETES MELLITUS, TYPE 1; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; METHYLATION; MICE; MODELS, BIOLOGICAL; RNA, UNTRANSLATED;

EID: 80054769498     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.11.78     Document Type: Review

References (79)

1. Opie EL. The relation of diabetes mellitus to lesions of the pancreas. Hyaline degeneration of the islands of Langerhans. J. Exp. Med. 25(5), 527-540 (1901).
2. Gale EA. The rise of childhood Type 1 diabetes in the 20th century. Diabetes 51(12), 3353-3361 (2002). (Pubitemid 35403436)
3. Baschal EE, Eisenbarth GS. Extreme genetic risk for type 1A diabetes in the post-genome era. J. Autoimmun. 31(1), 1-6 (2008).
4. Haffner SM. Epidemiology of Type 2 diabetes risk factors. Diabetes Care 21(Suppl. 3), 3C-6C (1998).
5. Ounissi-Benkalha H, Polychronakos C. The molecular genetics of Type 1 diabetes: new genes and emerging mechanisms. Trends Mol. Med. 14(6), 268-275 (2008).
6. Barrett JC, Clayton DG, Concannon P, et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of Type 1 diabetes. Nat. Genet. 41(6), 703-707 (2009).
7. Todd JA. Etiology of Type 1 diabetes. Immunity 32(4), 457-467 (2010).
8. Roep BO, Peakman M. Surrogate end points in the design of immunotherapy trials: emerging lessons from Type 1 diabetes. Nat. Rev. Immunol. 10(2), 145-152 (2010).
9. Akerblom HK, Reunanen A. The epidemiology of insulin-dependent diabetes mellitus (IDDM) in Finland and in northern Europe. Diabetes Care 8(Suppl. 1), 10-16 (1985). (Pubitemid 16226382)
10. Hyttinen V, Kaprio J, Kinnunen L, Koskenvuo M, Tuomilehto J. Genetic liability of Type 1 diabetes and the onset age among 22,650 young Finnish twin pairs: a nationwide follow-up study. Diabetes 52(4), 1052-1055 (2003). (Pubitemid 36384278)
11. Ling C, Groop L. Epigenetics: a molecular link between environmental factors and Type 2 diabetes. Diabetes 58(12), 2718-2725 (2009).
12. van Speybroeck L. From epigenesis to epigenetics: the case of C. H. Waddington. Ann. NY Acad. Sci. 981, 61-81 (2002). (Pubitemid 36127086)
13. Jenuwein T, Allis CD. Translating the histone code. Science 293(5532), 1074-1080 (2001). (Pubitemid 32758077)
14. Felsenfeld G, Groudine M. Controlling the double helix. Nature 421(6921), 448-453 (2003). (Pubitemid 36157954)
15. Esteller M. Epigenetics in cancer. N. Engl. J. Med. 358(11), 1148-1159 (2008).
16. Feinberg AP. Epigenomics reveals a functional genome anatomy and a new approach to common disease. Nat. Biotechnol. 28(10), 1049-1052 (2010).
17. Patel T, Patel V, Singh R, Jayaraman S. Chromatin remodeling resets the immune system to protect against autoimmune diabetes in mice. Immunol. Cell Biol. 89(5), 640-649 (2011).
18. Miao F, Smith DD, Zhang L, Min A, Feng W, Natarajan R. Lymphocytes from patients with Type 1 diabetes display a distinct profile of chromatin histone H3 lysine 9 dimethylation: an epigenetic study in diabetes. Diabetes 57(12), 3189-3198 (2008).
19. Hasan S, Hottiger MO. Histone acetyl transferases: a role in DNA repair and DNA replication. J. Mol. Med. 80(8), 463-474 (2002). (Pubitemid 34983911)
20. Brandl A, Heinzel T, Krmer OH. Histone deacetylases: salesmen and customers in the post-translational modification market. Biol. Cell. 101(4), 193-205 (2009).
21. Soutoglou E, Viollet B, Vaxillaire M, Yaniv M, Pontoglio M, Talianidis I. Transcription factor-dependent regulation of CBP and P/CAF histone acetyltransferase activity. EMBO J. 20(8), 1984-1992 (2001). (Pubitemid 32397400)
22. Gray SG, de Meyts P. Role of histone and transcription factor acetylation in diabetes pathogenesis. Diabetes Metab. Res. Rev. 21(5), 416-433 (2005). (Pubitemid 41320653)
23. Marks PA, Richon VM, Breslow R, Rifkind RA. Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. 13(6), 477-483 (2001). (Pubitemid 33027900)
24. Smith KT, Workman JL. Histone deacetylase inhibitors: anticancer compounds. Int. J. Biochem. Cell. Biol. 41(1), 21-25 (2009).
25. Bertrand P. Inside HDAC with HDAC inhibitors. Eur. J. Med. Chem. 45(6), 2095-2116 (2010).
26. Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene 363, 15-23 (2005). (Pubitemid 41691888)
27. Li B, Samanta A, Song X, et al. FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. Proc. Natl Acad. Sci. USA 104(11), 4571-4576 (2007). (Pubitemid 47186266)
28. Miremadi A, Oestergaard MZ, Pharoah PD, Caldas C. Cancer genetics of epigenetic genes. Hum. Mol. Genet. 16 (Spec. No 1), R28-R49 (2007). (Pubitemid 47241841)
29. Villagra A, Sotomayor EM, Seto E. Histone deacetylases and the immunological network: implications in cancer and inflammation. Oncogene 29(2), 157-173 (2010).
30. Chen SS, Jenkins AJ, Majewski H. Elevated plasma prostaglandins and acetylated histone in monocytes in Type 1 diabetes patients. Diabet. Med. 26(2), 182-186 (2009).
31. Miao F, Gonzalo IG, Lanting L, Natarajan R. In vivo chromatin remodeling events leading to inflammatory gene transcription under diabetic conditions. J. Biol. Chem. 279(17), 18091-18097 (2004). (Pubitemid 38560579)
32. Wen Y, Gu J, Li SL, Reddy MA, Natarajan R, Nadler JL. Elevated glucose and diabetes promote interleukin-12 cytokine gene expression in mouse macrophages. Endocrinology 147(5), 2518-2525 (2006).
33. Gudbjörnsdottir S, Eliasson B, Eeg-Olofsson K, Zethelius B, Cederholm J, on behalf of the National Diabetes Register (NDR). Additive effects of glycaemia and dyslipidaemia on risk of cardiovascular diseases in Type 2 diabetes: an observational study from the Swedish National Diabetes Register. Diabetologia 54(10), 2544-2551 (2011).
34. Takahashi I, Miyaji H, Yoshida T, Sato S, Mizukami T. Selective inhibition of IL-2 gene expression by trichostatin A, a potent inhibitor of mammalian histone deacetylase. J. Antibiot. (Tokyo) 49(5), 453-457 (1996). (Pubitemid 26178952)
35. van Lint C, Emiliani S, Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr. 5(4-5), 245-253 (1996).
36. Skov S, Rieneck K, Bovin LF, et al. Histone deacetylase inhibitors: a new class of immunosuppressors targeting a novel signal pathway essential for CD154 expression. Blood 101(4), 1430-1438 (2003). (Pubitemid 36182517)
37. Reilly CM, Thomas M, Gogal R Jr, et al. The histone deacetylase inhibitor trichostatin A upregulates regulatory T cells and modulates autoimmunity in NZB/W F1 mice. J. Autoimmun. 31(2), 123-130 (2008).
38. Tao R, de Zoeten EF, Ozkaynak E, et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat. Med. 13(11), 1299-1307 (2007). (Pubitemid 350073591)
39. You S, Slehoffer G, Barriot S, Bach JF, Chatenoud L. Unique role of CD4+CD62L+ regulatory T cells in the control of autoimmune diabetes in T cell receptor transgenic mice. Proc. Natl Acad. Sci. USA 101(Suppl. 2), 14580-14585 (2004). (Pubitemid 39346727)
40. Makino S, Kunimoto K, Muraoka Y, Mizushima Y, Katagiri K, Tochino Y. Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu 29(1), 1-13 (1980). (Pubitemid 10185796)
41. André I, Gonzalez A, Wang B, Katz J, Benoist C, Mathis D. Checkpoints in the progression of autoimmune disease: lessons from diabetes models. Proc. Natl. Acad. Sci. USA 93(6), 2260-2263 (1996). (Pubitemid 26104338)
42. Li X, Kazgan N. Mammalian sirtuins and energy metabolism. Int. J. Biol. Sci. 7(5), 575-587 (2011).
43. Lugo-Villarino G, Maldonado-Lopez R, Possemato R, Penaranda C, Glimcher LH. T-bet is required for optimal production of IFN-g and antigen-specific T cell activation by dendritic cells. Proc. Natl Acad. Sci. USA 100(13), 7749-7754 (2003). (Pubitemid 36760041)
44. Matsuda JL, George TC, Hagman J, Gapin L. Temporal dissection of T-bet functions. J. Immunol. 178(6), 3457-3465 (2007). (Pubitemid 46417610)
45. Wilson CB, Rowell E, Sekimata M. Epigenetic control of T-helper-cell differentiation. Nat. Rev. Immunol. 9(2), 91-105 (2009).
46. Placek K, Coffre M, Maiella S, Bianchi E, Rogge L. Genetic and epigenetic networks controlling T helper 1 cell differentiation. Immunology 127(2), 155-162 (2009).
47. Sobel DO, Han J, Williams J, Yoon JW, Jun HS, Ahvazi B. g interferon paradoxically inhibits the development of diabetes in the NOD mouse. J. Autoimmun. 19(3), 129-137 (2002). (Pubitemid 35341862)
48. Qin HY, Chaturvedi P, Singh B. In vivo apoptosis of diabetogenic T cells in NOD mice by IFN-g/TNF-a. Int. Immunol. 16(12), 1723-1732 (2004). (Pubitemid 40003860)
49. Jain R, Tartar DM, Gregg RK, et al. Innocuous IFNg induced by adjuvant-free antigen restores normoglycemia in NOD mice through inhibition of IL-17 production. J. Exp. Med. 205(1), 207-218 (2008). (Pubitemid 351185727)
50. Hu X, Ivashkiv LB. Cross-regulation of signaling pathways by interferon-g: implications for immune responses and autoimmune diseases. Immunity 31(4), 539-550 (2009).
51. Gysemans C, Callewaert H, Overbergh L, Mathieu C. Cytokine signalling in the b-cell: a dual role for IFNg. Biochem. Soc. Trans. 36(Pt 3), 328-333 (2008). (Pubitemid 351839325)
52. Eaves IA, Wicker LS, Ghandour G, et al. Combining mouse congenic strains and microarray gene expression analyses to study a complex trait: the NOD model of Type 1 diabetes. Genome Res. 12(2), 232-243 (2002). (Pubitemid 34162990)
53. Hui DY, Howles PN. Carboxyl ester lipase: structure-function relationship and physiological role in lipoprotein metabolism and atherosclerosis. J. Lipid Res. 43(12), 2017-2030 (2002). (Pubitemid 35471067)
54. David JR, Al-Askari S, Lawrence HS, Thomas L. Delayed hypersensitivity in vitro: I. The specificity of inhibition of cell migration by antigens. J. Immunol. 93, 264-273 (1964).
55. Jayaraman S, Muthukkaruppan VR. In vitro correlate of transplantation immunity: spleen cell migration inhibition in the lizard, Calotes versicolor. Dev. Comp. Immunol. 1(2), 133-143 (1977).
56. Jayaraman S, Mohan R, Muthukkaruppan VR. Relationship between migration inhibition and plaque-forming cell responses to sheep erythrocytes in the teleost, Tilapia mossambica. Dev. Comp. Immunol. 3(1), 67-75 (1979). (Pubitemid 9169873)
57. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 6(1), 6-21 (2002). (Pubitemid 34049633)
58. Watanabe Y, Maekawa M. Methylation of DNA in cancer. Adv. Clin. Chem. 52, 145-167 (2010).
59. Mackay DJ, Temple IK. Transient neonatal diabetes mellitus Type 1. Am. J. Med. Genet. C Semin. Med. Genet. 154C(3), 335-342 (2010).
60. Bell CG, Teschendorff AE, Rakyan VK, Maxwell AP, Beck S, Savage DA. Genome-wide DNA methylation analysis for diabetic nephropathy in Type 1 diabetes mellitus. BMC Med. Genomics 3, 33 (2010).
61. Penn NW, Suwalski R, ORiley C, Bojanowski K, Yura R. The presence of 5- hydroxymethylcytosine in animal deoxyribonucleic acid. Biochem. J. 126(4), 781-790 (1972).
62. Nestor C, Ruzov A, Meehan R, Dunican D. Enzymatic approaches and bisulfite sequencing cannot distinguish between 5-methylcytosine and 5-hydroxymethylcytosine in DNA. Biotechniques 48(4), 317-319 (2010).
63. Pociot F, Akolkar B, Concannon P, et al. Genetics of Type 1 diabetes: whats next Diabetes 59(7), 1561-1571 (2010).
64. Steck AK, Rewers MJ. Genetics of Type 1 diabetes. Clin. Chem. 57(2), 176-185 (2011).
65. Ridgway WM, Peterson LB, Todd JA, et al. Gene-gene interactions in the NOD mouse model of Type 1 diabetes. Adv. Immunol. 100, 151-157 (2008).
66. Karvonen M, Viik-Kajander M, Moltchanova E, Libman I, LaPorte R, Tuomilehto J. Incidence of childhood Type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetes Care 23(10), 1516-1526 (2000).
67. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N. Engl. J. Med. 347(12), 911-920 (2002).
68. Hober D, Sauter P. Pathogenesis of Type 1 diabetes mellitus: interplay between enterovirus and host. Nat. Rev. Endocrinol. 6(5), 279-289 (2010).
69. MacFarlane A, Strom A, Scott F. Epigenetics: deciphering how environmental factors may modify autoimmune Type 1 diabetes. Mamm. Genome 20(9-10), 624-632 (2009).
70. Mathers JC, Strathdee G, Relton CL. Induction of epigenetic alterations by dietary and other environmental factors. Adv. Genet. 71, 3-39 (2010).
71. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 136(2), 215-233 (2009).
72. Ambros V. MicroRNAs: genetically sensitized worms reveal new secrets. Curr. Biol. 20(14), R598-R600 (2010).
73. van Rooij E, Liu N, Olson EN. MicroRNAs flex their muscles. Trends Genet. 24(4), 159-166 (2008).
74. Gaur A, Jewell DA, Liang Y, et al. Characterization of miRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res. 67(6), 2456-2468 (2007). (Pubitemid 46548930)
75. Zhou L, He H, Mi JX, Li C, Lee B, Mi QS. MiRNA genes. Ann. NY Acad. Sci. 1150, 72-75 (2008).
76. Wright MW, Bruford EA. Naming junk: human non-protein coding RNA (ncRNA) gene nomenclature. Hum. Genomics 5(2), 90-98 (2011).
77. Jayaraman S, Patel T, Patel V, et al. Transfusion of nonobese diabetic mice with allogeneic newborn blood ameliorates autoimmune diabetes and modifies the expression of selected immune response genes. J. Immunol. 184(6), 3008-3015 (2010).
78. Oliver SS, Denu JM. Dynamic interplay between histone H3 modifications and protein interpreters: emerging evidence for a "histone language". Chembiochem 12(2), 299-307 (2011).
79. Lee JS, Smith E, Shilatifard A. The language of histone crosstalk. Cell 142(5), 682-685 (2010).